Colchicine Savings Program to End 12/31/23

By: | | Topics : Colchicine, Mitigare,

Mitigare® True Blue Savings Program Ends This Month

West-Ward Pharmaceuticals Inc. (now Hikma Pharmaceuticals USA Inc.) changed the Colchicine market in 2016 by introducing Mitigare® (Colchicine) 0.6mg Capsules for prophylaxis of gout flares in adults.1 Soon after the launch of Mitigare®, the company introduced the True Blue Savings program—the first and only co-pay program for Colchicine Capsules. Although the True Blue Savings program has helped many eligible gout patients save money on their Colchicine therapy over the years, the program will
end December 31, 2023.

How Mitigare® made Colchicine affordable

In 2006, the US Food and Drug Administration (FDA) announced a new initiative to promote testing of medicines in use prior to the agency’s existence. Despite the fact that Colchicine had been used to prevent gout flares for hundreds of years, unapproved formulations of the drug were banned a few years later. The FDA approved Colcrys® (colchicine, USP) 0.6 mg tablets in 2009,2 which launched at a significantly higher price than pre-existing unapproved Colchicine generics. Patients were forced to pay a premium price for Colcrys® because it was the only FDA-approved Colchicine product available at that time. The launch of Mitigare® (and the subsequent launch of Authorized Generic Colchicine Capsules) was important because it gave people with gout a reasonably priced alternative to Colcrys®.

How the True Blue Savings program helped eligible patients save on Colchicine

Although the launches of Mitigare® and Authorized Generic Colchicine Capsules helped make Colchicine therapy more affordable for people with gout, Hikma wanted to give eligible patients the opportunity to save even more. Thus, the True Blue Savings program was born. The True Blue Savings program was the first and only Colchicine co-pay program available to consumers. It offered eligible patients the opportunity to pay as little as $0 per month for their Colchicine therapy.

You may still be able to save on Mitigare®

Although the True Blue Savings program will be discontinued on December 31, 2023, you may still be able to save on Mitigare®. One possible way is with GoodRx. When on the site, search “Mitigare” to check out pricing at local pharmacies. If you are uninsured or underinsured, you may be able to access discounts on Colchicine with the InsideRx® pharmacy discount card.

Thank you for participating

Hikma Pharmaceuticals USA Inc. appreciates its valued customers and is grateful for their loyalty. Although the True Blue Savings program will end on December 31, 2023, Mitigare® and Authorized Generic Colchicine Capsules will continue to be available at pharmacies nationwide. If you have questions about Mitigare® or Authorized Generic Colchicine Capsules, please call Hikma Pharmaceuticals USA Inc. Customer Service at 1-800-631-2174.

 

Mitigare® is a registered trademark of Hikma Pharmaceuticals USA Inc.

All other registered trademarks are the property of their respective owners.

Please see the full Prescribing Information and Medication Guide for Mitigare® for complete product details.

NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Hikma’s recommendations for gout flare prevention, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.

HK-2401-v1

References

  1. Mitigare® (Colchicine) 0.6mg Capsules [prescribing information]. Columbus, OH: West-Ward Columbus, Inc.; 2019.
  2. Colchicine (marketed as Colcrys) Information. US Food and Drug Administration website. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information- patients-and-providers/colchicine-marketed-colcrys-information. Accessed December 11, 2023.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.